2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Breast Neoplasms
20
Prostatic Neoplasms
7
Triple Negative Breast Neoplasms
6
Ovarian Neoplasms
4
Neoplasm Metastasis
4
Melanoma
3
Lymphoma
3
Lung Neoplasms
3
Hematologic Neoplasms
3
Endometrial Neoplasms
3
Uterine Cervical Neoplasms
2
Recurrence
2
Neoplasms
2
Multiple Myeloma
2
Locally Advanced (Inoperable) or Metastatic Breast Cancer
2
Leukemia
2
Healthy Participants
2
Disease Progression
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumour
1
Rectal Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Interventions
Rituximab
226
Cyclophosphamide
202
fludarabine phosphate
108
Peripheral Blood Stem Cell Transplantation
103
Filgrastim
87
Etoposide
76
Cytarabine
70
ibrutinib
68
Mycophenolic Acid
67
Bortezomib
66
Whole-Body Irradiation
63
Cyclosporine
63
Melphalan
59
Lenalidomide
59
Bendamustine Hydrochloride
58
Vincristine
53
Radiotherapy
53
fludarabine
52
Tacrolimus
50
Doxorubicin
48
Busulfan
48
Methotrexate
47
Antilymphocyte Serum
42
Prednisone
41
Carmustine
40
Dexamethasone
38
Granulocyte Colony-Stimulating Factor
33
venetoclax
32
acalabrutinib
31
zanubrutinib
26
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Mantle-Cell
×
capivasertib
×
Clear all
NCT05008055
2024-12-20
CAPITAL
AstraZeneca
Phase 2
Completed
30 enrolled
15 charts